This episode is the first of 2 podcasts based on a live presentation on treatment strategies and management of treatment-related adverse events for patients with hepatocellular carcinoma (HCC). Listen as 2 experts discuss the latest data supporting the optimal treatment of patients with HCC, with topics including: the current challenges in the management of HCC, recommended initial workup strategies, and the evolving treatment landscape in HCC.
To access episode 2, click here.
After completing this activity, participants should be better able to:
- Summarize current and emerging biomarkers and their impact on HCC treatment choice
- Identify the roles of novel and emerging agents in the treatment of advanced HCC
- Use recommended strategies to recognize and manage AEs associated with novel treatments for HCC
Oncology NPs, PAs, and nurses
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
Nursing contact hours: 0.50, which includes 0.50 hours of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid until February 24, 2023. PAs should only claim credit commensurate with the extent of their participation.
PA Course Advisor: Jessica Garner, DMSc, PA-C, University of the Pacific, Sacramento, California
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credits for learning and change.
This program is cosupported by educational grants from Bristol-Myers Squibb; Eisai; and Merck Sharp & Dohme Corp.
This activity is supported by educational grants from Eisai and Merck Sharp & Dohme Corp.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr O’Brien: fees for non-CME/CE services: Amgen, Novartis.
Dr Singal: consulting fees: AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Exelixis, Genentech, Roche.
Dr Yarchoan: consulting fees: AstraZeneca, Eisai, Exelixis, Genentech; other financial or material support: Bristol-Myers Squibb, Incyte.
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Listen to the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
The estimated time to complete this activity is 0.50 hours.
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of 100%.
Release date: February 25, 2022
Expiration date: February 24, 2023
© 2022 Practicing Clinicians Exchange. All Rights Reserved. 103421-POD5A